言語を選択

Galectin-9

Galectin-9 詳細

英語名	Galactoside-binding lectin Galectin 9	市販薬剤の数	0
治験薬の数	2	ターゲットの別称	Ecalectin，Tumor antigen HOM-HD-21，Galectin-9，Lectin， Galactoside-Binding， Soluble， 9，LGALS9
研究＆開発段階	Phase 2 Clinical

英語名	Galactoside-binding lectin Galectin 9
ターゲットの別称	Ecalectin，Tumor antigen HOM-HD-21，Galectin-9，Lectin， Galactoside-Binding， Soluble， 9，LGALS9
市販薬剤の数	0
治験薬の数	2
研究＆開発段階	Phase 2 Clinical

Galectin-9 製品リスト

属性
Protein (3)
製品ライブラリ
オンライン (3)
種
Human (3)
タグ
His Tag (1)His Tag & Avi Tag (1)Tag Free (1)
マーカー
Unconjugated (2)Biotin-labeled (1)

製品番号	種	発現システム	製品説明
LG9-H5213	Human	HEK293	Human Galectin-9 / LGALS9 Protein, Tag Free (MALS verified)
LG9-H5244	Human	HEK293	Human Galectin-9 / LGALS9 Protein, His Tag, low endotoxin
LG9-H82H3	Human	HEK293	Biotinylated Human Galectin-9 / LGALS9 Protein, His,Avitag™

総数量3

Galectin-9バックグランド

Galectin-9 (LGALS9) is also known as tumor antigen HOM-HD-21 and ecalectin. Galectins are a family of proteins defined by their binding specificity for β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. As for Galectin-9, it has high affinity for the Forssman pentasaccharide, and it is also the ligand for HAVCR2/TIM3. Forthermore, Galectin-9 stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth.

Galectin-9分子の別称

Galectin-9,LGALS9,Ecalectin

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
LYT-200	LYT-200	Phase 2 Clinical	Puretech Health	Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours	詳細
Anti-Gal9 antibody (Fibrogen)	FG-3165; HFB-200901; HFB-200902; HFB2009; HFB2009 series; HFB9-2	Phase 1 Clinical	HiFiBiO Therapeutics	Solid tumours	詳細